Abstract:Liver X receptors (LXRs) have been recognized as a promising therapeutic target for atherosclerosis; however, their role in insulin sensitivity is controversial. Adiponectin plays a unique role in maintaining insulin sensitivity. Currently, no systematic experiments elucidating the role of LXR activation in insulin function based on adiponectin signaling have been reported. Here, we investigated the role of LXR activation in insulin resistance based on adiponectin signaling, and possible mechanisms. C57BL/6 mice maintained on a regular chow received the LXR agonist, T0901317 (30 mg/kg.d) for 3 weeks by intraperitoneal injection, and differentiated 3T3-L1 adipocytes were treated with T0901317 or GW3965. T0901317 treatment induced significant insulin resistance in C57BL/6 mice. It decreased adiponectin gene transcription in epididymal fat, as well as serum adiponectin levels. Activity of AMPK, a key mediator of adiponectin signaling, was also decreased, resulting in decreased Glut-4 membrane translocation in epididymal fat. In contrast, adiponectin activity was not changed in the liver of T0901317 treated mice. In vitro, both T0901317 and GW3965 decreased adiponectin expression in adipocytes in a dose-dependent manner, an effect which was diminished by LXR alpha silencing. ChIP-qPCR studies demonstrated that T0901317 decreased the binding of PPAR gamma to the PPAR-responsive element (PPRE) of the adiponectin promoter in a dose-dependent manner. Furthermore, T0901317 exerted an antagonistic effect on the expression of adiponectin in adipocytes co-treated with 3 mu M Pioglitazone. In luciferase reporter gene assays, T0901317 dose-dependently inhibited PPRE-Luc activity in HEK293 cells co-transfected with LXR alpha and PPAR gamma. These results suggest that LXR activation induces insulin resistance with decreased adiponectin signaling in epididymal fat, probably due to negative regulation of PPAR gamma signaling. These findings indicate that the potential of LXR activation as a therapeutic target for atherosclerosis may be limited by the possibility of exacerbating insulin resistance-related disease.

Liver X receptors：the new orientation of drugs for metabolic diseases

Liver X receptors as potential therapeutic targets for multiple diseases.

Recent Advances on Liver X Receptors

Liver X Receptors And Their Agonists: Targeting For Cholesterol Homeostasis And Cardiovascular Diseases

New Drug Targets LXR for Cholesterol Control

Research progress on antiatherosclerosis mechanism of liver X receptors

The Prospect of Liver X Receptor(LXR) in Cardiovascular Disease

[Liver X Receptor: Crucial Mediator in Lipid and Carbohydrate Metabolism].

Liver X Receptors As Potential Therapeutic Targets in Atherosclerosis

Recent Advance of LXR Affect on Cholesterol Homeostasis

Liver X receptors bridge hepatic lipid metabolism and inflammation.

LXR agonists: new potential therapeutic drug for neurodegenerative diseases

Discovery of novel liver X receptor inverse agonists as lipogenesis inhibitors

Liver X receptor: a potential target in the treatment of atherosclerosis

Targeting Liver X Receptors for the Treatment of Non-Alcoholic Fatty Liver Disease

Transcriptional Regulation of Lipid Biosynthesis, Related Target Validation and Drug Discovery

Discovery of Tissue Selective Liver X Receptor Agonists for the Treatment of Atherosclerosis Without Causing Hepatic Lipogenesis.

Regulation Of Insulin Resistance And Adiponectin Signaling In Adipose Tissue By Liver X Receptor Activation Highlights A Cross-Talk With Ppar Gamma

Natural Products Targeting Liver X Receptors or Farnesoid X Receptor

FXR: structures, biology, and drug development for NASH and fibrosis diseases

Structurally Selective Mechanism of Liver X Receptor Ligand: in Silico and in Vitro Studies.